PFIZER INC — Form 8-K
Filed November 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Pfizer reported Q3 2026 revenues of $16.6B (flat YoY); excluding COVID products, revenues grew 7% operationally. Launched/acquired products grew 32% operationally. Company raised full-year 2026 revenue guidance by $1.5B midpoint to $62.0–$64.0B and raised adjusted diluted EPS guidance to $2.95–$3.05 (previously $2.80–$3.00). Cecile Guegan appointed CFO effective November 1, 2026. Key drivers: Eliquis +25%, Padcev +55%, Vyndaqel +12%; offsets included Paxlovid −63%, Comirnaty −29%, Prevnar −10%.
Why this rating
Guidance raise and strong non-COVID growth are encouraging for large pharma, but COVID collapse and mature-product erosion create offsetting headwinds. Material but not transformational relative to $138B market cap.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.